Non-invasive direct current brain stimulation: the evidence behind the hype by Nord, CL & Roiser, JP
cl in ical  art icle
Non-invasive direct 
current brain stimulation 
for depression:  
the evidence behind the hype 
Camilla L Nord  
is an MRC/Brain Research Trust-
funded PhD student at the Institute 
of Cognitive Neuroscience (ICN), 
University College London (UCL). 
Her main research interest is 
the development of fMRI and 
behavioural measures to predict 
clinical risk and outcome in 
psychiatric disorders. She completed 
her undergraduate training at the 
University of Oxford and an MSc 
at UCL. She is currently running a 
clinical trial investigating the neural 
and cognitive effects of brain 
stimulation in depression. 
Jonathan P Roiser 
is Professor of Neuroscience and 
Mental Health at the ICN, UCL, 
and a Wellcome Trust Senior 
Investigator. His research addresses 
the cognitive and neural basis of 
mental health problems, especially 
depression. Following undergraduate 
and PhD training at the University 
of Cambridge and the National 
Institute of Mental Health, and 
post-doctoral work at the UCL 
Institute of Neurology, he joined 
the ICN and founded the Cognitive 
Neuropsychiatry group. The group’s 
research has been funded by the 
Medical Research Council, the British 
Academy, the Brian and Behavior 
Research Foundation and the 
Wellcome Trust. 
Correspondence to:  
Camilla L Nord 
UCL Institute of Cognitive 
Neuroscience
17 Queen Square, London WC1N 3AZ
Email: camilla.nord.11@ucl.ac.uk
Conflict of interest statement:
The authors report no conflicts of 
interest. 
Provenance and peer review:
Submitted and externally reviewed.
To cite:
Nord CL, Roiser JP. 
ACNR 2015;15(5):9-11.
T he leading global cause of disability is major depression, affecting over 350 million people worldwide.1 Pharmacological and 
psychological therapies for depression have 
changed very little in the past thirty years, despite 
extensive research for new treatment targets. 
The most common antidepressant drugs are 
effective for about 58% of depressed patients in 
primary care, while 45% respond to placebo.2 
The difficulty in developing new treatments 
arises in part because depression is a disorder of 
unknown aetiology. The neurobiological correl-
ates of depression, on the other hand, are not 
entirely unknown: neuroscience research has 
identified several brain circuits that operate 
abnormally in depression. Recently, this know-
ledge has contributed to the development of 
experimental treatments, including those that 
stimulate the brain directly in a targeted manner. 
Among these novel treatments is a form of 
painless, noninvasive brain stimulation termed 
transcranial direct current stimulation (tDCS), 
commonly applied to the dorsolateral prefrontal 
cortex (DLPFC) in trials for depression. The 
practical advantages of tDCS are many: tDCS is 
comparatively inexpensive, portable, and safe. 
In this article we discuss the evidence that tDCS 
is effective in depression, and the neural and 
cognitive mechanisms that may drive its putative 
antidepressant effect. We also outline the import-
ance of mechanistic studies of DLPFC tDCS to 
clarify its effects on the brain, and optimise its 
potential for clinical use. 
What does tDCS do?
The use of weak electrical currents to stimulate 
the brain is not new, with reports dating back 
to the early 19th century.3 Mild brain stimula-
tion such as tDCS has benefited from recent 
computational modelling and neuroimaging 
studies aimed at refining stimulation parameters, 
including electrode size, current amplitudes, 
location and durations of stimulation.4 tDCS uses 
a weak electric current to stimulate a localised 
area of the brain (‘direct’ indicates that the 
current flows in a single direction, in contrast to 
‘alternating’ current stimulation). In early litera-
ture it was simply termed “polarisation”, referring 
to its effects on neuronal resting potentials.5 
Recent depression trials place the anodal 
electrode over the left DLPFC, with the cath-
odal electrode used as a ‘ground’ electrode, for 
instance supraorbitally. In this specific example, 
this creates an electrical circuit with current trav-
elling from the anodal (positive) to the cathodal 
(negative) electrode. This delivers low levels of 
electrical stimulation through the skull immedi-
ately under the anode, typically between 1 and 
2 milliamps, with a small proportion of that 
affecting the cortex beneath, facilitating (but 
not directly evoking) neuronal activity in part 
through its effects on the resting potential (see 
below). Although the entire physiological effect 
is likely more complex, this general potentiation 
of activity has been reported to produce marked 
behavioural effects in domains as varied as 
motor tasks, auditory learning, and language.6 
It is because of different electrode montages—
electrode placement and current amplitude—
that this technology can claim to modulate such 
an improbably diverse set of cognitive processes, 
including those involved in depression. 
Summary
• There is a major need for novel therapies 
in depression. One that has been suggested 
is transcranial direct current stimulation 
(tDCS), a form of mild, non-invasive 
electrical brain stimulation
• tDCS has been used effectively as an 
intervention for major depression, both 
alone and as an augmentative therapy 
combined with antidepressant medication
• Few studies have explored the neural 
mechanisms underlying the putative 
antidepressant effect of tDCS
• An improved understanding of the 
mechanisms underlying the antidepressant 
effect of tDCS is vital for enhancing 
clinical efficacy and predicting response to 
treatment, but this technique shows great 
potential as a safe, effective, and cost-
effective therapy
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Table 1: Summary of key studies investigating the basis of tDCS as a treatment for MDD. RCT: Randomised controlled trial,  
HAM-D: Hamilton Rating Scale-Depression, BDI: Beck Depression Inventory, EEG: electroencephalography. 
Study Key finding Limitations
Fregni8 • Pilot RCT:  5-session tDCS induced significant decreases in HAM-D and BDI • Very small sample size (N = 10)
Loo9 • Large RCT: modest effect of tDCS after 3 weeks daily stimulation
• Effect strengthened after 6 weeks
• All patients on stable antidepressant medication
Brunoni10 • RCT: combined tDCS + antidepressant medication more effective than 
either therapy alone
• No cognitive/neural correlates 
Shiozawa11 • Meta-analysis: active tDCS statistically superior to sham in depression 
trials 
• Effect sizes vary somewhat between studies
• Low number of trials
• Results specific to short term effects (no long-term 
trials)
Powell14 • EEG study: tDCS induces changes over medial frontal cortex during 
working memory performance
• Extends understanding of tDCS neurophysiology to MDD 
• Single session
• Small sample size (N=18)
Why target the DLPFC?
One of the most established neural correlates 
of depression is abnormal metabolism in the 
DLPFC. Resting-state studies (e.g. using posi-
tron emission tomography: PET) tend to find 
a reduction in DLPFC activity in depressed 
patients, which normalises somewhat 
following symptom remission; by contrast, 
task-related activation (e.g. during working 
memory) is generally increased in the DLPFC 
in depression.7 Lesion studies also support the 
hypothesis of DLPFC dysfunction in depres-
sion: patients with lesions involving the DLPFC 
show higher levels of depression than patients 
with lesions sparing the DLPFC.7 
Increased task-related DLPFC neural acti-
vation is often interpreted as cortical ineffi-
ciency. While the primary role of the DLPFC is 
in so-called ‘executive’ function and cognitive 
control, it also plays a central role in emotion 
regulation, particularly in the reappraisal and 
suppression of negative emotions.7 Thus, 
targeting the DLPFC with tDCS aims to remedy 
inefficiency in emotion regulation that could 
be central to depressive symptoms. 
Clinical trials of tDCS in depression
The first double-blind, sham-controlled clin-
ical trial of tDCS for depression reported 
very pronounced effects of tDCS on mood 
symptoms8 following a relatively short stimu-
lation period. Differences between active and 
sham (placebo) tDCS even persisted over the 
succeeding month. 
Less marked (but nonetheless substantial) 
effects of tDCS were later reported in a three-
week trial: tDCS improved mood significantly 
more than sham, but no difference between 
active and sham was found in response rates.9 
Cognitive effects were also smaller than 
reported in previous trials, with attention and 
working memory improvements found after 
the first tDCS session, but no (expected) cumu-
lative cognitive enhancements independent 
of mood effects. More recently, a clinical trial 
found tDCS and sertraline to have comparable 
effects, but combined tDCS-sertraline treat-
ment was more effective than either treatment 
alone.10 However, null results have also been 
reported, and some studies find substantially 
larger effect sizes than others (see Figure 1).11
Differences in stimulation parameters, 
outcome measures, and timing of tDCS 
delivery could all account for variation in 
tDCS effectiveness. In the next few years, clin-
ical trials should clarify the optimal schedule 
for tDCS intervention in depression (typically 
trials have administered stimulation five times 
per week), and only after this can large-scale 
trials determine whether it should be offered 
as an alternative treatment option. Very 
few serious side effects have been reported 
in any tDCS trials for depression, with the 
most common including temporary itching, 
tingling, or skin redness, and very limited 
reports of hypomania.9,10 Thus, tDCS has great 
potential as a novel, safe, effective treatment 
for depression, but this can be realised only if 
the specific mechanisms and optimal stimula-
tion parameters can be identified.4 
Discovering the mechanisms of tDCS in 
depression
Advances in the clinical development of tDCS 
will be boosted by improved understanding 
of the neurophysiological mechanisms under-
lying its behavioural effects. tDCS has polar-
ity-specific effects on neuronal membrane 
potential: anodal tDCS decreases the resting 
membrane potential of the neuronal soma, 
increasing the likelihood of depolarisation, 
whereas cathodal tDCS raises the membrane 
potential of the soma towards hyperpolarisa-
tion12 (see Figure 2). More widespread neural 
changes (i.e. away from the stimulation site), 
and local non-neuronal effects have also been 
reported, including local changes in ionic 
concentrations, levels of cyclic adenosine 
monophosphate (cAMP), protein synthesis, 
and NMDA receptor efficacy.4,6
Figure 1.
Forest plot of effect sizes (Hedges’ g) to illustrate the relative strength of treatment effects for each selected study, 
including the overall effect (vertical dotted line), the standardised mean difference (SMD), and confidence interval (CI). 
Figure reproduced with permission from Shiozawa et al, Int J Neuropsychopharmacol. 2014:11;1–10.
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Unfortunately for the purposes of under-
standing the effect of tDCS in depression, 
the neurophysiological mechanisms of 
tDCS have been studied predominantly in 
the motor cortex. The mechanisms driving 
‘antidepressant’ tDCS over the DLPFC are 
poorly understood, though most studies 
corroborate the simple anodal-excitatory/
cathodal-inhibitory model (though note that 
mild anodal currents can sometimes inhibit 
neuronal activity13). 
One study investigating the neuro-
physiology of DLPFC tDCS found a polar-
ity-specific effect on both working memory 
performance and EEG measures: anodal 
tDCS increased both behavioural perform-
ance and its electrophysiological correlates, 
while cathodal stimulation decreased both 
measures.6 In currently-depressed patients, 
tDCS was reported to induce neurophysio-
logical changes extending over the medial 
frontal cortex during working memory 
performance.14 These studies provide insight 
into the role of the DLPFC in depression, 
indicating that tDCS might alter DLPFC effi-
ciency as well as its interaction with more 
widespread prefrontal regions, driving the 
resulting behavioural and mood changes. 
To date, most research on tDCS for depres-
sion has adopted one of two strategies: trials 
to determine whether tDCS improves depres-
sive symptoms; or experimental studies, 
usually in healthy subjects, to determine its 
mechanism of effect. This division inhibits a 
better understanding of the specific mech-
anisms driving the antidepressant effects 
of tDCS. Studies combining both strategies 
have the ability to resolve this, and deter-
mine how tDCS could best target symptoms 
of depression. 
Proceed cautiously—but not too 
cautiously
The most well-known electrical therapy 
in psychiatry is electroconvulsive therapy 
(ECT). Although evidence strongly indi-
cates that ECT is an effective short-term 
treatment for depression,15 it is perceived 
negatively by the public and its therapeutic 
efficacy is often tempered by concerns 
about cognitive side-effects. In the case 
of tDCS, which uses stimulation currents 
that are orders of magnitude lower than 
ECT, initial reports of cognitive enhance-
ment with tDCS reignited public interest in 
electrical current stimulation. From these 
reports emerged an online community of 
‘home kit’ tDCS users who report finding 
amazing effects, sometimes far beyond what 
has been shown experimentally. Within the 
neuroscience community, researchers have 
begun to question the magnitude of the 
reported benefits of tDCS.16 An improved 
understanding of its mechanisms and effects 
is key to resolving these debates. 
The challenge for basic and translational 
tDCS researchers is to convince clinicians 
that it is a credible experimental treatment, 
with the caveat that understanding its mech-
Figure 2. 
Diagram of a typical tDCS setup for depression, with the anodal electrode over the left DLPFC (red) and cathodal elec-
trode over the ipsilateral shoulder (blue). Note the direction of current towards the brain in the case of anodal stimu-
lation, and outward in the case of cathodal stimulation. Insert: schematic illustration of neuronal resting membrane 
potential without tDCS, and after anodal (red) and cathodal (blue) tDCS. 
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anisms will no doubt involve many more years 
of cellular, neurophysiological, and cognitive 
research. Putting treatment before mechanism 
is common in psychiatry: the neural mechan-
isms of proven effective treatments—cognitive 
therapy, electroconvulsive therapy, and many 
psychiatric drugs—are still relatively poorly 
understood. Still, history need not dictate 
future treatment discovery, and the tools of 
neuroscience can illuminate the biological 
and behavioural effects of tDCS alongside 
tests of its clinical efficacy. tDCS is only one 
of a number of experimental treatments for 
depression with origins in neuroscience, but 
it may hold particular potential as a new 
therapy, or as an augmentative strategy for 
existing therapies. The key will be honing the 
technology to target the complex and hetero-
genous nature of this debilitating disorder.
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